Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice

British Journal of Pharmacology

Volumn 130, Issue 6, 2000, Pages 1425-1431

  Popik, Piotr ^a   Kozela, Ewa ^a   Pilc, Andrzej ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Analgesia; Fentanyl; Group II metabotropic receptors; LY354740; Memantine; Morphine; NMDA receptor antagonist; Pain; Tolerance

Indexed keywords

EGLUMETAD; FENTANYL; GLUTAMATE RECEPTOR AGONIST; MEMANTINE; METABOTROPIC RECEPTOR; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG INHIBITION; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

EID: 0033914156     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703438     Document Type: Article

References (49)

1. ATTWELL, P.J., KAURA, S., SIGALA, G., BRADFORD, H.F., CROUCHER, M.J., JANE, D.E. & WATKINS, J.C. (1995). Blockade of both epileptogenesis and glutamate release by (1S,3S)-ACPD, a presynaptic glutamate receptor agonist. Brain Res., 698, 155-162.
2. ATTWELL, P.J., KOUMENTAKI, A., ABDUL-GHANI, A.S., CROUCHER, M.J. & BRADFORD, H.F. (1998a). Specific group II metabotropic glutamate receptor activation inhibits the development of kindled epilepsy in rats. Brain Res., 787, 286-291.
3. ATTWELL, P.J., SINGH, K.N., JANE, D.E., CROUCHER. M.J. & BRADFORD, H.F. (1998b). Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2′R, 3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res., 805, 138-143.
4. BATTAGLIA, G., MONN, J.A. & SCHOEPP, D.D. (1997). In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett., 229, 161-164.
5. BELOZERTSEVA, I.V. & BESPALOV, A.Y. (1998). Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice. Naunyn-Schmied. Arch. Pharmacol., 358, 270-274.
6. BILSKY, E.J., INTURRISI, C.E., SADEE, W., HRUBY, V.J. & PORRECA, F. (1996) Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain, 68, 229-237.
7. BISAGA, A. & POPIK, P. (2000). In search of a new pharmacological treatment of drug addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend., 59, 1-15.
8. BOND, A., MONN, J.A. & LODGE, D. (1997). A novel orally active group 2 metabotropic glutamate receptor agonist: LY 354740. Neuro Report, 8, 1463-1466.
9. CAPPENDIJK, S.L., DE VRIES, R. & DZOLJIC, M.R. (1993). Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol., 3, 111-116.
10. COCHIN, J. & KORNETSKY, C. (1964). Development and loss of tolerance to morphine in the rat after single and multiple injections. J. Pharmacol. Exp. Ther., 145, 1-10.
11. CONN, P.J. & PIN, J.P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 37, 205-237.
12. DANYSZ, W., PARSONS, C.G., BRESINK, I. & QUACK, G. (1995a). Glutamate in CNS disorders. Drug News Perspect., 8, 261-277.
13. DANYSZ, W., ZAJACZKOWSKI, W. & PARSONS, C.G. (1995b). Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol., 6, 455-474.
14. DUMAN, R.S. & ENNA, S.J. (1986). A procedure for measuring alpha 2-adrenergic receptor-mediated inhibition of cyclic AMP accumulation in rat brain slices. Brain Res., 384, 391-394.
15. HUMAN. R.S., TALLMAN, J.F. & NESTLER, E.J. (1988). Acute and chronic opiate-regulation of adenylate cyclase in brain: specific-effects in locus coerulcus. J. Pharmacol. Exp. Ther., 246, 1033-1039.
16. ELLIOTT, K., HYNANSKY, A. & INTURRISI, C.E. (1994b). Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain, 59, 361-368.
17. ELLIOTT, K., MINAMI, N., KOLESNIKOV, Y.A., PASTERNAK, G.W. & INTURRISI, C.E. (1994a). The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, Ng-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain, 56, 69-75.
18. POLE Y, K.M. (1991). Clinical tolerance to opioids. In Towards a New Pharmacotherapy of Pain: Report of the Dahlem Workshop: Beyond Morphine, cds. A.I. Busbaum & J.M. Besson. pp. 181-204. New York: John Wiley.
19. GLAUM, S.R. & MILLER, R.J. (1994). Acute Regulation of Synaptic Transmission by Metabotropic Glutamate Receptors. In The Metabotropic Glutamate Receptors, eds. P.J. Conn & J. Patel. pp. 147-172. Totowa, NJ: Humana Press.
20. GOLD, M.S., REDMOND, E.D. & KLEBER, H.D. (1978). Clonidine blocks acute opiate withdrawal symptoms. Lancet 2, 599-601.
21. GONZALEZ, P., CABELLO, P., GERMANY, A., NORRIS, B. & CONTRERAS, E. (1997). Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol., 332, 257-262.
22. HELTON, D.R., TIZZANO, J.P., MONN, J.A., SCHOEPP, D.D. & KALLMAN, M.J. (1998). Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther., 284, 651-660.
23. JOHNSON, J.T., MATTIUZ, E.L., HORNG, J.S. & SWANSON, S.P. (1997). The disposition of a selective metabotropic glutamate receptor 2 (MGLUR2) agonist (LY354740) in rats and dogs. Pharmaceut. Res., 14 (Suppl 11), S-82.
24. KLODZINSKA, A., CHOJNACKA WOJCIK, E., PALUCHA, A., BRANSKI, P., POPIK, P. & PILC, A. (1999). Potential anti-anxiety and anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology, 38, 1831-1839.
25. LAULIN, J.P., CELERIER, E., LARCHER, A., LEMOAL, M. & SIMONNET, G. (1999). Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience, 89, 631-636.
26. LOVINGER, D.M. & MCCOOL, B.A. (1995). Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGluR2 or 3. J. Neurophysiol., 73, 1076-1083.
27. LUTFY, K., HURLBUT, D.E. & WEBER, E. (1993). Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res., 616, 83-88.
28. LUTFY, K., SHEN, K.Z., KWON, I.S., CAI, S.X., WOODWARD, R.M., KEANA, J.F.W. & WEBER, E. (1995). Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor glycine site antagonist. Eur. J. Pharmacol., 273, 187-189.
29. MAREK, P., BEN-ELIYAHU, S., GOLD, M. & LIEBESKIND, J.C. (1991). Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res., 547, 77-81.
30. MARTIN, G., PRZEWLOCKI, R. & SIGGINS, G.R. (1999). Chronic morphine treatment selectively augments metabotropic glutamate receptor-induced inhibition of N-methyl-D-aspartate receptor-mediated neurotransmission in nucleus accumbens. J. Pharmacol. Exp. Ther., 288, 30-35.
31. MISZTAL, M. & DANYSZ, W. (1995). Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav. Pharmacol., 6, 550-561.
32. MONAGHAN. D.T., BRIDGES, R.J. & COTMAN, C.W. (1989). The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Ann. Rev. Pharmacol. Toxicol., 29, 365-402.
33. MONN, J.A., VALLI, M.J., MASSEY, S.M., WRIGHT, R.A., SALHOFF, C.R., JOHNSON, B.G., HOWE, T., ALT, C.A., RHODES, G.A., ROBEY, R.L., GRIFFEY, K.R., TIZZANO, J.P., KALLMAN, M.J., HELTON. D.R. & SCHOEPP, D.D. (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]-hexane-2,6-dicarboxylic acid (LY 354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem., 40, 528-537.
34. NESTLER, E.J. (1993). Cellular responses to chronic treatment with drugs of abuse. Crit. Rev. Neurobiol., 7, 23-39.
35. PARONIS, C.A. & HOLTZMAN, S.O. (1991). Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. J. Pharmacol. Exp. Ther., 259, 582-589.
36. PETRALIA, R.S., WANG, Y.X., NIEDZIELSKI, A.S. & WENTHOLD, R.J. (1996). The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience, 71, 949-976.
37. PIN, J.P. & DUVOISIN, R. (1995). The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 34, 1-26.
38. POPIK, P. & DANYSZ, W. (1997). Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by NMDA receptor antagonist, memantine. J. Pharmacol. Exp. Ther., 280, 854-865.
39. POPIK, P. & KOZELA, E. (1999). Clinically available NMDA antagonist, memantine attenuates tolerance to analgesic effects of morphine in a mouse tail flick test. Pol. J. Pharmacol., 51, 223-231.
40. POPIK, P., KOZELA, E. & DANYSZ, W. (2000). Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to analgesic effects of morphine in a mouse tail flick test. Naunyn-Schmied. Arch. Pharmacol., 361, 425-432.
41. POPIK, P. & SKOLNICK, P. (1996). The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav., 53, 791-798.
42. SCHAFFHAUSER, H., CARTMELL, J., JAKOB, R.R. & MUTEL, V. (1997). Pharmacological characterization of metabotropic glutamate receptors linked to the inhibition of adenylate cyclase activity in rat striatal slices. Neuropharmacology, 36, 933-940.
43. SCHOEPP D.D., JOHNSON, B.C. & MONN, J.A. (1992). Inhibition of cyclic-AMP formation by a selective metabotropic glutamate receptor agonist. J. Neurochem., 58, 1184-1186.
44. SHIGEMOTO, R., KINOSHITA, A., WADA, E., NOMURA, S., OHISHI, H., TAKADA, M., FLOR, P.J., NEKI, A., ABE, T., NAKANISHI, S. & MIZUNO, N. (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci., 17, 7503-7522.
45. SIEGEL, S. (1976). Morphine analgesic tolerance: Its situation specificity supports a Pavlovian conditioning model. Science, 193, 323-325.
46. TRUJILLO, K.A. & AKIL, H. (1991). Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 251, 85-87.
47. UGOLINI, A. & BORDI, F. (1995). Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus. Eur. J. Pharmacol., 294, 403-410.
48. VANDERGRIFF, J. & RASMUSSEN, K. (1999). The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coerulcus neurons and behavioral signs of morphine withdrawal. Neuropharmacology, 38, 217-222.
49. WALKER, E.A., RICHARDSON, T.M. & YOUNG, A.M. (1997). Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology, 133, 17-28.